N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells

Cancer Cell

Volumn 29, Issue 4, 2016, Pages 536-547

  Lee, John K ^a,b   Phillips, John W ^b   Smith, Bryan A ^b   Park, Jung Wook ^b   Stoyanova, Tanya ^b   McCaffrey, Erin F ^b   Baertsch, Robert ^c   Sokolov, Artem ^c   Meyerowitz, Justin G ^d,e,f   Mathis, Colleen ^b   Cheng, Donghui ^b   Stuart, Joshua M ^c   Shokat, Kevan M ^b,d,f   Gustafson, W Clay ^d,g   Huang, Jiaoti ^a,b   Witte, Owen N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California Santa Cruz   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKT1 PROTEIN; CHGA PROTEIN; CHROMOGRANIN A; CYTOKERATIN 8; DOXYCYCLINE; ENO2 PROTEIN; HEPATOCYTE NUCLEAR FACTOR 3BETA; MYC PROTEIN; NCAM1 PROTEIN; NERVE CELL ADHESION MOLECULE; NEURAL CELL ADHESION MOLECULE 1; PROTEIN; PROTEIN KINASE B; PROTEIN P63; SYNAPTOPHYSIN; SYP PROTEIN; THYROID TRANSCRIPTION FACTOR 1; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; ALISERTIB; ANTINEOPLASTIC AGENT; AURKA PROTEIN, HUMAN; AURORA A KINASE; AZEPINE DERIVATIVE; CARBANILAMIDE DERIVATIVE; CD532 COMPOUND; HYBRID PROTEIN; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TUMOR PROTEIN;

ARTICLE; BASAL CELL; CASTRATION RESISTANT PROSTATE CANCER; CELL PLASTICITY; CELL SURFACE; CONTROLLED STUDY; EC50; EPITHELIUM BASAL CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUROENDOCRINE PROSTATE CANCER; NONHUMAN; ONCOGENE C MYB; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE EPITHELIUM CELL; PROSTATECTOMY; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CELL TRANSFORMATION; DRUG SCREENING; ENZYME ACTIVATION; EPITHELIUM CELL; EXOME; GENE EXPRESSION REGULATION; GENETIC TRANSDUCTION; GENETICS; LASER CAPTURE MICRODISSECTION; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; NONOBESE DIABETIC MOUSE; ONCOGENE MYC; ORCHIECTOMY; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SCID MOUSE; TUMOR CELL LINE; TUMOR INVASION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; AURORA KINASE A; AZEPINES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; EPITHELIAL CELLS; EXOME; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; LASER CAPTURE MICRODISSECTION; MALE; MICE, INBRED NOD; MICE, SCID; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; NEUROENDOCRINE TUMORS; ORCHIECTOMY; PHENYLUREA COMPOUNDS; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; PYRIMIDINES; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962090106     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.03.001     Document Type: Article

References (48)

1. Beltran H. The N-myc oncogene: maximizing its targets, regulation, and therapeutic potential. Mol. Cancer Res. 2014, 12:815-822.
2. Beltran H., Rickman D.S., Park K., Chae S.S., Sboner A., MacDonald T.Y., Wang Y., Sheikh K.L., Terry S., Tagawa S.T., et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011, 1:487-495.
3. Beltran H., Tomlins S., Aparicio A., Arora V., Rickman D., Ayala G., Huang J., True L., Gleave M.E., Soule H., et al. Aggressive variants of castration-resistant prostate cancer. Clin. Cancer Res. 2014, 20:2846-2850.
4. Berman-Booty L.D., Knudsen K.E. Models of neuroendocrine prostate cancer. Endocr. Relat. Cancer 2015, 22:R33-R49.
5. Boutros P.C., Fraser M., Harding N.J., de Borja R., Trudel D., Lalonde E., Meng A., Hennings-Yeomans P.H., McPherson A., Sabelnykova V.Y., et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat. Genet. 2015, 47:736-745.
6. Brockmann M., Poon E., Berry T., Carstensen A., Deubzer H.E., Rycak L., Jamin Y., Thway K., Robinson S.P., Roels F., et al. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell 2013, 24:75-89.
7. Carney D.N., Bunn P.A., Gazdar A.F., Pagan J.A., Minna J.D. Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung. Proc. Natl. Acad. Sci. USA 1981, 78:3185-3189.
8. Choi N., Zhang B., Zhang L., Ittmann M., Xin L. Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell 2012, 21:253-265.
9. Chong J.A., Tapia-Ramirez J., Kim S., Toledo-Aral J.J., Zheng Y., Boutros M.C., Altshuller Y.M., Frohman M.A., Kraner S.D., Mandel G. REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell 1995, 80:949-957.
10. Clermont P.L., Lin D., Crea F., Wu R., Xue H., Wang Y., Thu K.L., Lam W.L., Collins C.C., Wang Y., et al. Polycomb-mediated silencing in neuroendocrine prostate cancer. Clin. Epigenetics 2015, 7:40.
11. Dang C.V. MYC on the path to cancer. Cell 2012, 149:22-35.
12. Epstein J.I., Amin M.B., Beltran H., Lotan T.L., Mosquera J.-M., Reuter V.E., Robinson B.D., Troncoso P., Rubin M.A. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am. J. Surg. Pathol. 2014, 38:756-767.
13. Fleming W.H., Hamel A., MacDonald R., Ramsey E., Pettigrew N.M., Johnston B., Dodd J.G., Matusik R.J. Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res. 1986, 46:1535-1538.
14. Gao L., Schwartzman J., Gibbs A., Lisac R., Kleinschmidt R., Wilmot B., Bottomly D., Coleman I., Nelson P., McWeeney S., et al. Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS One 2013, 8:e63563.
15. Goldstein A.S., Lawson D.A., Cheng D., Sun W., Garraway I.P., Witte O.N. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc. Natl. Acad. Sci. USA 2008, 105:20882-20887.
16. Goldstein A.S., Huang J., Guo C., Garraway I.P., Witte O.N. Identification of a cell of origin for human prostate cancer. Science 2010, 329:568-571.
17. Grasso C.S., Wu Y.M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., Quist M.J., Jing X., Lonigro R.J., Brenner J.C., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
18. Gray I.C., Stewart L.M., Phillips S.M., Hamilton J.A., Gray N.E., Watson G.J., Spurr N.K., Snary D. Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br. J. Cancer 1998, 78:1296-1300.
19. Gustafson W.C., Meyerowitz J.G., Nekritz E.A., Chen J., Benes C., Charron E., Simonds E.F., Seeger R., Matthay K.K., Hertz N.T., et al. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell 2014, 26:414-427.
20. Hansel D.E., Nakayama M., Luo J., Abukhdeir A.M., Park B.H., Bieberich C.J., Hicks J.L., Eisenberger M., Nelson W.G., Mostwin J.L., et al. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate 2009, 69:603-609.
21. Helpap B., Kollermann J., Oehler U. Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives. Urol. Int. 1999, 62:133-138.
22. Hu Y., Smyth G.K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 2009, 347:70-78.
23. Huang M., Weiss W.A. Neuroblastoma and MYCN. Cold Spring Harbor Perspect. Med. 2013, 3:a014415.
24. Jain M., Arvanitis C., Chu K., Dewey W., Leonhardt E., Trinh M., Sundberg C.D., Bishop J.M., Felsher D.W. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002, 297:102-104.
25. Jenkins R.B., Qian J., Lieber M.M., Bostwick D.G. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 1997, 57:524-531.
26. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., Chan K.W., Ciceri P., Davis M.I., Edeen P.T., et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26:127-132.
27. Karthaus W.R., Iaquinta P.J., Drost J., Gracanin A., van Boxtel R., Wongvipat J., Dowling C.M., Gao D., Begthel H., Sachs N., et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 2014, 159:163-175.
28. Kawauchi D., Robinson G., Uziel T., Gibson P., Rehg J., Gao C., Finkelstein D., Qu C., Pounds S., Ellison D.W., et al. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell 2012, 21:168-180.
29. Lin D., Wyatt A.W., Xue H., Wang Y., Dong X., Haegert A., Wu R., Brahmbhatt S., Mo F., Jong L., et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 2014, 74:1272-1283.
30. Mirosevich J., Gao N., Gupta A., Shappell S.B., Jove R., Matusik R.J. Expression and role of Foxa proteins in prostate cancer. Prostate 2006, 66:1013-1028.
31. Mosquera J.M., Beltran H., Park K., MacDonald T.Y., Robinson B.D., Tagawa S.T., Perner S., Bismar T.A., Erbersdobler A., Dhir R., et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 2013, 15:1-10.
32. Ni M., Chen Y., Fei T., Li D., Lim E., Liu X.S., Brown M. Amplitude modulation of androgen signaling by c-MYC. Genes Dev. 2013, 27:734-748.
33. Otto T., Horn S., Brockmann M., Eilers U., Schuttrumpf L., Popov N., Kenney A.M., Schulte J.H., Beijersbergen R., Christiansen H., et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009, 15:67-78.
34. Rapa I., Ceppi P., Bollito E., Rosas R., Cappia S., Bacillo E., Porpiglia F., Berruti A., Papotti M., Volante M. Human ASH1 expression in prostate cancer with neuroendocrine differentiation. Mod. Pathol. 2008, 21:700-707.
35. Shen R., Dorai T., Szaboles M., Katz A.E., Olsson C.A., Buttyan R. Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium. Urol. Oncol. 1997, 3:67-75.
36. Shen H., Powers N., Saini N., Comstock C.E., Sharma A., Weaver K., Revelo M.P., Gerald W., Williams E., Jessen W.J., et al. The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res. 2008, 68:10154-10162.
37. Spiess P.E., Pettaway C.A., Vakar-Lopez F., Kassouf W., Wang X., Busby J.E., Do K.A., Davuluri R., Tannir N.M. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 2007, 110:1729-1737.
38. Stephenson R.A., Dinney C.P., Gohji K., Ordonez N.G., Killion J.J., Fidler I.J. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J. Natl. Cancer Inst. 1992, 84:951-957.
39. Stoyanova T., Cooper A.R., Drake J.M., Liu X., Armstrong A.J., Pienta K.J., Zhang H., Kohn D.B., Huang J., Witte O.N., et al. Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc. Natl. Acad. Sci. USA 2013, 110:20111-20116.
40. Sutherland K.D., Proost N., Brouns I., Adriaensen D., Song J.Y., Berns A. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 2011, 19:754-764.
41. Tan H.L., Sood A., Rahimi H.A., Wang W., Gupta N., Hicks J., Mosier S., Gocke C.D., Epstein J.I., Netto G.J., et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin. Cancer Res. 2014, 20:890-903.
42. Valastyan S., Weinberg R.A. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147:275-292.
43. Wang W., Epstein J.I. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am. J. Surg. Pathol. 2008, 32:65-71.
44. Wang X., Julio M.K.-d., Economides K.D., Walker D., Yu H., Halili M.V., Hu Y.-P., Price S.M., Abate-Shen C., Shen M.M. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009, 461:495-500.
45. Williamson S.R., Zhang S., Yao J.L., Huang J., Lopez-Beltran A., Shen S., Osunkoya A.O., MacLennan G.T., Montironi R., Cheng L. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod. Pathol. 2011, 24:1120-1127.
46. Wu X., Senechal K., Neshat M.S., Whang Y.E., Sawyers C.L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA 1998, 95:15587-15591.
47. Wu C.H., van Riggelen J., Yetil A., Fan A.C., Bachireddy P., Felsher D.W. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc. Natl. Acad. Sci. USA 2007, 104:13028-13033.
48. Yao J.L., Madeb R., Bourne P., Lei J., Yang X., Tickoo S., Liu Z., Tan D., Cheng L., Hatem F., et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am. J. Surg. Pathol. 2006, 30:705-712.